The lowering of the price target by Evercore ISI Group suggests a less optimistic view on NovoCure's future performance, which could lead to short-term downward pressure on the stock price. The 'In-Line' rating indicates that the stock is expected to perform in line with the market, but the reduced price target reflects potential challenges or lower growth expectations.